Boundless Bio Common Stock Today
| BOLD Stock | USD 1.16 0.02 1.69% |
PerformanceWeakest
| Odds Of DistressStrong
|
Boundless Bio is trading at 1.16 as of the 2nd of February 2026, a 1.69 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.13. Boundless Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 4th of November 2025 and ending today, the 2nd of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of March 2024 | Category Healthcare | Classification Health Care |
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics, Inc. The company has 22.39 M outstanding shares of which 52.76 K shares are currently shorted by private and institutional investors with about 0.4 trading days to cover. More on Boundless Bio Common
Moving together with Boundless Stock
Moving against Boundless Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Boundless Stock Highlights
| President CEO | Zachary Hornby | ||||
| Old Names | [21Shares Bytetree BOLD ETP, 21Shares Bytetree BOLD ETP, 21S BOLD, 21Shares Bytetree BOLD ETP EUR] | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBy employing borrowed capital, Boundless Bio can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Boundless Bio's use of financial leverage and reveals what portion of Boundless Bio's asset base relies on creditor financing.
| |||||
Boundless Bio Common (BOLD) is traded on NASDAQ Exchange in USA and employs 64 people. Boundless Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.97 M. Boundless Bio Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 22.39 M outstanding shares of which 52.76 K shares are currently shorted by private and institutional investors with about 0.4 trading days to cover.
Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Boundless Bio Probability Of Bankruptcy
Ownership AllocationBoundless Bio holds a total of 22.39 Million outstanding shares. Over half of Boundless Bio's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Boundless Ownership Details
Boundless Bio Historical Income Statement
Boundless Stock Against Markets
Boundless Bio Corporate Management
| Christian Hassig | Chief Officer | Profile | |
| James MD | Interim Officer | Profile | |
| Jamilu Rubin | Chief Officer | Profile | |
| Shailaja Kasibhatla | Senior Development | Profile | |
| Peter Krein | Senior Medicine | Profile | |
| Anthony Pinkerton | Senior Discovery | Profile | |
| Amy Berkley | Senior Team | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.